TRABD2A: A Potential Drug Target and Biomarker (G129293)

Target Name: TRABD2A

NCBI ID: G129293

TRABD2A

TRABD2A: A Potential Drug Target and Biomarker

TRABD2A, also known as TRABD2A2, is a protein that is expressed in various tissues and cells in the body. It is a member of the TRABD2 family, which is characterized by the presence of a unique domains that are involved in the regulation of various cellular processes. One of the most interesting aspects of TRABD2A is its potential as a drug target and biomarker.

The TRABD2A protein is known to play a role in the regulation of the onset of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its functions include the regulation of cell adhesion, migration, and invasion, as well as the regulation of the production of various signaling molecules.

One of the most promising aspects of TRABD2A is its potential as a drug target. The TRABD2A protein has been shown to interact with various signaling molecules, including TGF-β1, NF-kappa-B, and SMAD. These interactions suggest that TRABD2A could be a useful target for drugs that are designed to modulate these signaling pathways.

In addition to its potential as a drug target, TRABD2A also has the potential as a biomarker. Its expression has been shown to be associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This suggests that TRABD2A could be a useful biomarker for these diseases, and could be used to diagnose and monitor the progression of these conditions.

TRABD2A has also been shown to play a role in the regulation of cellular processes that are important for tissue growth and development. Its functions include the regulation of cell proliferation, differentiation, and migration, as well as the regulation of cell-cell adhesion.

These properties make TRABD2A an attractive candidate for drug development. By modulating the signaling pathways that are involved in these processes, drugs could be developed that treat a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In conclusion, TRABD2A is a protein that has the potential to be a drug target and biomarker. Its unique domains and its functions in the regulation of cellular processes make it an attractive candidate for drug development. Further research is needed to fully understand the role of TRABD2A in various diseases and to develop drugs that can effectively target it.

Protein Name: TraB Domain Containing 2A

Functions: Metalloprotease that acts as a negative regulator of the Wnt signaling pathway by mediating the cleavage of the 8 N-terminal residues of a subset of Wnt proteins. Following cleavage, Wnt proteins become oxidized and form large disulfide-bond oligomers, leading to their inactivation. Able to cleave WNT3A, WNT5, but not WNT11. Required for head formation

The "TRABD2A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRABD2A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets